Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABOSTO:BOUL -0.26%47 OCF Margin % is 11.52% as of Mar. 2026, which is 33% above its 10-year median of 8.67. GuruFocus rates OSTO:BOUL with a GF Score™ of 47/100 and a GF Value™ of kr7.14 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 53.8% on this metric.
The historical rank and industry rank for Boule Diagnostics AB's OCF Margin % or its related term are showing as below:
OSTO:BOUL'
s OCF Margin % Range Over the Past 10 Years
Min: -2.07 Med: 8.67 Max: 18.79
Current: 4.26
During the past 13 years, the highest OCF Margin % of Boule Diagnostics AB was 18.79%. The lowest was -2.07%. And the median was 8.67%.
OSTO:BOUL's OCF Margin % is ranked worse than 53.8% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 5.785
vs OSTO:BOUL: 4.26
Boule Diagnostics AB OCF Margin % Related Terms
Boule Diagnostics AB OCF Margin % Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:BOUL vs ABT, SYK, MDT: OCF Margin % Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (OSTO:BOUL) has a OCF Margin % of 11.52% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Boule Diagnostics AB and its competitors. This is 33% above median its historical median of 8.67. According to the industry distribution chart, Boule Diagnostics AB ranks #439 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 53.8%.
Is Boule Diagnostics AB's OCF Margin % too high?
Boule Diagnostics AB's current OCF Margin % of 11.52% is 33% above median its 10-year median of 8.67. The Medical Devices & Instruments industry median OCF Margin % is 5.79. Boule Diagnostics AB's value of 11.52% is 99.1% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #439 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #439 out of 816 companies for OCF Margin %. This places Boule Diagnostics AB in the lower half of its industry. The industry median OCF Margin % is 5.79. Boule Diagnostics AB's value of 11.52% is 99.1% above this benchmark. While the company's 10-year median is 8.67 vs. the industry median of 5.79, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.79, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current OCF Margin % of 11.52% is 99.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current OCF Margin % is 11.52%, which is 33% above median its own 10-year median of 8.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Boule Diagnostics AB (OSTO:BOUL) is currently considered Possible Value Trap. The stock's GF Value™ is kr7.14, compared to a current price of kr3.80 — trading 46.8% below its estimated fair value. The current OCF Margin % is 11.52%, which is 33% above median its 10-year median of 8.67 and 99.1% above the Medical Devices & Instruments industry median of 5.79. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Boule Diagnostics AB (OSTO:BOUL), the current OCF Margin % is 11.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (OSTO:BOUL) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr3.80 is trading 46.8% below its estimated GF Value™ of kr7.14.
GuruFocus considers Boule Diagnostics AB to be Possible Value Trap.
Key valuation signals for OSTO:BOUL:
OCF Margin %: 11.52% (33% above median its 10-year median of 8.67)
GF Value™: kr7.14 vs. price of kr3.80 (46.8% below fair value)
Industry Position: 99.1% above the Medical Devices & Instruments median (#439 of 816)
No single metric tells the full story. See the OSTO:BOUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for OSTO:BOUL
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:BOUL has been successfully added to your 
